Cingulate Inc. (CING) Income Statement

NASDAQ: CINGRevenue, profits, margins and EPS over 7 years.

CING 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Research & development+3.5%
$9.8M
2025 · hover or tap a bar for each year
2019: $9.1M2020: $5.1M (−44.0%)2021: $8.4M (+65.1%)2022: $9.0M (+7.0%)2023: $15.5M (+72.2%)2024: $9.4M (−39.0%)2025: $9.8M (+3.5%)
20192025
Operating expenses+27.4%
$19.9M
2025 · hover or tap a bar for each year
2019: $11.5M2020: $6.2M (−45.6%)2021: $20.7M (+231.3%)2022: $17.5M (−15.4%)2023: $22.8M (+30.0%)2024: $15.6M (−31.3%)2025: $19.9M (+27.4%)
20192025
Operating income
−$19.9M
2025 · hover or tap a bar for each year
2019: −$11.6M2020: −$7.1M2021: −$20.7M2022: −$17.5M2023: −$22.8M2024: −$15.6M2025: −$19.9M
20192025
Net income
−$22.4M
2025 · hover or tap a bar for each year
2019: −$11.5M2020: −$7.2M2021: −$20.7M2022: −$17.9M2023: −$23.5M2024: −$16.6M2025: −$22.4M
20192025
EPS (diluted)
−$4.32
2025 · hover or tap a bar for each year
2020: −$5.082021: −$2.052022: −$278.812023: −$300.462024: −$30.182025: −$4.32
20192025

CING revenue and net income

RevenueNet incomeNet margin (right axis)

CING growth rates

to 2025
1 year3 years5 years10 years
Revenue————
Gross profit————
Operating income————
Net income————
EPS (diluted)————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

CING quarterly EPS vs estimates

Reported EPSAnalyst estimate

Cingulate beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.48).

CING income statement

Cingulate Inc. annual income statement
2025202420232022202120202019
Revenue$0$0$0$0$0$0$0
Cost of revenue$540,894$653,090$582,918$621,993$808,441$842,353$178,912
Gross profit−$540,894−$653,090−$582,918−$621,993−$808,441−$842,353−$178,912
Research & development$9.8M$9.4M$15.5M$9.0M$8.4M$5.1M$9.1M
Sales, general & admin$10.2M$6.2M$7.3M$8.5M$12.3M$2.0M$2.6M
Total operating expenses$19.9M$15.6M$22.8M$17.5M$20.7M$6.2M$11.5M
Operating income−$19.9M−$15.6M−$22.8M−$17.5M−$20.7M−$7.1M−$11.6M
Interest expense$924,446$99,000$776,000$174,000$33,407$54,605$0
Income before taxes−$22.4M−$16.6M−$23.5M−$17.7M−$20.7M−$7.2M−$11.5M
Income taxes—−$263$2$174,000$30,502$99,338−$100,528
Net income−$22.4M−$16.6M−$23.5M−$17.9M−$20.7M−$7.2M−$11.5M
EBITDA−$19.4M−$15.0M−$22.2M−$17.1M−$20.0M−$6.2M−$11.5M
EPS (diluted)−$4.32−$30.18−$300.46−$278.81−$2.05−$5.08—

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CING's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

CING financial results

Cingulate reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $22.4 million. Diluted earnings per share came to −$4.32.

See the CING stock overview for the latest quote and news, or the CING chart for price history and technical indicators.

CING income statement FAQ

Does Cingulate have revenue?

Cingulate reported no revenue for fiscal year 2025, which ended on December 31, 2025.

Is Cingulate profitable?

No. Cingulate reported a net loss of $22.4 million in fiscal 2025.

How much does Cingulate spend on research and development?

Cingulate spent $9.8 million on research and development in fiscal 2025.

What are Cingulate's earnings per share?

Cingulate earned $-4.32 per diluted share in fiscal 2025, compared with $-30.18 a year earlier.

When will Cingulate report its next earnings?

Cingulate is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.

When does Cingulate's fiscal year end?

Cingulate's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.

Biotechnology income statements